StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a report published on Thursday morning. The firm issued a hold rating on the stock. Can-Fite BioPharma Stock Up 1.8 % Shares of CANF opened at $2.23 on Thursday. Can-Fite BioPharma has a 52 week low of $1.52 and a 52 week […]
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology and inflammatory diseases, today announced its VP of Business.
StockNews.com Initiates Coverage on Can-Fite BioPharma (NYSE:CANF) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
PETACH TIKVA, Israel, February 28, 2024 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application titled "An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation". This invention addresses the use of Namodenoson for the
StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a report issued on Sunday. The brokerage issued a hold rating on the stock. Separately, HC Wainwright cut their target price on Can-Fite BioPharma from $34.00 to $18.00 and set a buy rating on the stock in a research report on Tuesday, […]